Paternal use of ribavirin-interferon alpha 2B combination therapy before conception

Canadian Family Physician

Volumn 51, Issue DEC., 2005, Pages 1623-1625

  Taguchi, Nobuko ^a,b   Ito, Shinya ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Motherisk Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGETRON; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CONCEPTION; DRUG EFFECT; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; FEMALE; HIGH RISK PREGNANCY; HUMAN; MALE; PREGNANCY; REPRODUCTION; RISK ASSESSMENT; DRUG COMBINATION; HEPATITIS C; REVIEW; SPERMATOZOON;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PATERNAL EXPOSURE; PREGNANCY; RIBAVIRIN; SPERMATOZOA;

EID: 33746439001     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24(Suppl 2):3-8.
2. Ahn J, Flamm S. Peginterferon-alpha (2b) and ribavirin. Expert Rev Anti Infect Ther 2004;2:17-25.
3. European Association for the Study of the Liver. International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999;30:956-61.
4. Vogel W. Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 2003;1:423-31.
5. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004;24(Suppl 2):97-104.
6. Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004;24(Suppl 2):47-54.
7. Pearlman BL. Hepatitis C treatment update. Am J Med 2004;117:344-52.
8. Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004;26:991-1025.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
11. Kiham L, Ferm VH. Congenital anomalies induced in hamster embryos with ribavirin. Science 1977;195:413-4.
12. Ferm VH, Willhite C, Kiham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978;17:93-102.
13. Jonson EM. The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies in experimental animals. J Am Coll Toxicol 1990;9:551-61.
14. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa, Ont: Canadian Pharmacists Association; 2004.
15. Westoff CF. Unintended pregnancy in America and abroad. Fam Plann Perspect 1998;20:254-61.
16. Trasler J, Doerksen T. Teratogen update: paternal exposures - reproductive risks. Teratology 1999;60:161-72.
17. Hegenbarth K, Maurer U, Kroisel PM, Fickert P, Trauner M, Stauber RE. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol 2001;96:2286-7.
18. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19(Suppl 1):67-75.
19. Bianca S, Ettore G. Male periconceptional ribavirin-ininterferon alpha-2b exposure with no adverse fetal effects. Birth Defects Res A Clin Mol Teratol 2003;67:77-8.
20. De Santis M, Carducci B, Cavaliere AF, De Santis L, Lucchese A, Straface G, et al. Paternal exposure to ribavirin: pregnancy and neonatal outcome. Antiviral Ther 2003;8:73-5.